SKY Vision Symposium Held in Suwon and Busan

SK Bioscience has re-highlighted the clinical value of its independently developed vaccines by sharing real-world evidence (RWE) with healthcare professionals nationwide.


SK Bioscience announced that it hosted the 'SKY Vision Symposium,' an academic event for medical professionals, at the Ramada Hotel in Suwon, Gyeonggi Province on July 14 and at the Lotte Hotel in Seomyeon, Busan on July 28.


Yusuan, Head of Domestic Marketing at SK Bioscience, is delivering a greeting to the attendees while hosting a symposium. SK Bioscience

Yusuan, Head of Domestic Marketing at SK Bioscience, is delivering a greeting to the attendees while hosting a symposium. SK Bioscience

View original image

At this symposium, the company presented the latest clinical research findings and real-world evidence accumulated in actual healthcare settings for its flu vaccine 'SKYCellflu,' shingles vaccine 'SKYZoster,' and RSV preventive antibody drug 'Beyfortus.'


With the flu, RSV, and shingles season approaching, the company has been recognized for expanding evidence-based vaccination strategies and demonstrating its competitiveness as a specialized vaccine company through active academic exchange.



Yoo Suan, Head of Domestic Marketing at SK Bioscience, stated, "We will continue to provide evidence-based information through ongoing academic exchange, contributing to public health promotion and the advancement of Korea's immunization environment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing